ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

1:00PM-3:00PM: Abstract Number: 0046

Baricitinib Ameliorates Residual Neuropathic Pain in Collagen Antibody-Induced Arthritis Mice by Suppressing Inflammation of the Dorsal Root Ganglion

RA – Animal Models Poster

1:00PM-3:00PM: Abstract Number: 0125

Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Initiating Mepolizumab

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

1:00PM-3:00PM: Abstract Number: 0276

Baseline Characteristics of and Early Outcomes in the First 200 Patients with RA Treated with Filgotinib in a Prospective Observational Study

RA – Treatment Poster I

1:00PM-3:00PM: Abstract Number: 0460

Baseline Glucocorticoid Toxicity in the Treatment of Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0022

Beneficial Structural Impact of Liraglutide, a GLP1 Receptor Agonist, in Three Inflammatory and Post-traumatic OA Animal Models

Osteoarthritis and Joint Biology – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 0409

Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0412

Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0411

Bimekizumab Improves Signs and Symptoms Including Inflammation in Patients with Active Ankylosing Spondylitis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

1:00PM-3:00PM: Abstract Number: 0013

Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

1:00PM-3:00PM: Abstract Number: 0340

Birth Order Is a Risk Factor for Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis

1:00PM-3:00PM: Abstract Number: 0094

Black Patients Are Less Satisfied with the Hospital Experience After Primary Hip and Knee Arthroplasty

Healthcare Disparities in Rheumatology Poster

1:00PM-3:00PM: Abstract Number: 0157

Brepocitinib for the Treatment of Dermatomyositis: Pharmacologic and Clinical Rationale

Muscle Biology, Myositis and Myopathies Poster I

1:00PM-3:00PM: Abstract Number: 0477

Can Beta-blockers Prevent Aortic Dilation in Patients with Giant Cell Arteritis and Large Vessel Vasculitis?

Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

1:00PM-3:00PM: Abstract Number: 0267

Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register

RA – Diagnosis, Manifestations, and Outcomes Poster I

1:00PM-3:00PM: Abstract Number: 0069

Capturing Clinical Reasoning in Real Time Reveals Low Rate of Serious Adverse Reactions Requiring B/tsDMARD Discontinuation in Inflammatory Joint Disease: An Analysis of the OPAL Real-World Dataset

Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

«Previous Page
1
…
3
4
5
6
7
…
39
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].